Luye Pharma Group Ltd. (HKG:2186)

Market Cap	10.39B +48.4%
Revenue (ttm)	7.02B +4.1%
Net Income	688.55M +31.1%
EPS	0.18 +26.7%
Shares Out	3.99B
PE Ratio	14.71
Forward PE	12.86
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26,422,500
Average Volume	21,348,818
Open	2.600
Previous Close	2.600
Day's Range	2.480 - 2.640
52-Week Range	1.900 - 4.490
Beta	0.92
RSI	45.51
Earnings Date	Aug 28, 2026

About Luye Pharma Group

Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People’s Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surg...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Employees: 5,115
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2186

Financial Performance

In 2025, Luye Pharma Group's revenue was 6.31 billion, an increase of 4.07% compared to the previous year's 6.06 billion. Earnings were 618.75 million, an increase of 31.12%.

Financial numbers in CNY